Zoetis Inc. (NYSE:ZTS) Stake Lowered by Lake Street Private Wealth LLC

Lake Street Private Wealth LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 27.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,021 shares of the company’s stock after selling 749 shares during the period. Lake Street Private Wealth LLC’s holdings in Zoetis were worth $329,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter worth about $31,000. First Personal Financial Services bought a new position in Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP acquired a new stake in Zoetis in the third quarter valued at approximately $33,000. Dunhill Financial LLC grew its position in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Quarry LP increased its stake in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 2.0 %

Shares of ZTS stock opened at $166.01 on Friday. The firm has a market capitalization of $74.90 billion, a P/E ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm’s fifty day simple moving average is $170.93 and its 200 day simple moving average is $179.95. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 EPS. The business’s revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ZTS shares. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.